Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Hsia

Gastroenterology Santa Maria, CA Medical Doctor

NPI 1508894486 CMS profile 22703

361 Town Center West Suite 101, Santa Maria, CA 93458

Open in the dashboard

General payments

$5,154

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Hsia of Santa Maria, CA is reported in the CMS Open Payments database as having received $5,154 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,709 67
2024 General $991 54
2023 General $886 42
2022 General $777 55
2021 General $470 35
2020 General $152 7
2019 General $169 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Hsia
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Thomas Hsia were reported at $1,709. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Thomas Hsia Gastroenterology median Middle half National median
2019 $169 $417 $126–$1,100 $163
2020 $152 $224 $74–$624 $114
2021 $470 $352 $106–$1,054 $132
2022 $777 $448 $129–$1,270 $149
2023 $886 $533 $150–$1,390 $160
2024 $991 $605 $160–$1,606 $164
2025 $1,709 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,813 170 payments
  2. Janssen Biotech, Inc. $397 24 payments
  3. Madrigal Pharmaceuticals $293 10 payments
  4. QOL Medical, LLC $262 10 payments
  5. Phathom Pharmaceuticals, Inc. $153 4 payments
  6. Ardelyx, Inc. $145 2 payments
  7. Gilead Sciences, Inc. $145 7 payments
  8. Aimmune Therapeutics, Inc. $131 3 payments
  9. Novo Nordisk Inc $123 1 payment
  10. Takeda Pharmaceuticals U.S.A., Inc. $103 6 payments
  11. Other $589 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,108 270 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $1,505 80 payments
  2. SKYRIZI Immunology $682 32 payments
  3. SKYRIZI Immunology $652 39 payments
  4. LINZESS $494 33 payments
  5. CREON $429 30 payments
  6. STELARA $397 24 payments
  7. REZDIFFRA $264 9 payments
  8. HUMIRA $262 22 payments
  9. MAVYRET $228 17 payments
  10. Sucraid $218 7 payments
  11. Other $1,666 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

600

Median for Gastroenterology: 569

Drug cost

$183,274

Median for Gastroenterology: $104,976

Branded share of claims

21%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 15 $51,218
Creon Lipase/Protease/Amylase Brand 19 $38,987
Linzess Linaclotide Brand 38 $33,336
Viberzi Eluxadoline Brand 18 $23,636
Ibsrela Tenapanor Hcl Brand 12 $20,873
Dexlansoprazole Dr Dexlansoprazole Brand 11 $4,824
Famotidine Generic 232 $2,783
Sucralfate Generic 47 $2,430
Mesalamine Generic 12 $1,824
Omeprazole Generic 61 $881

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$197,954

Medicare's payments for the services billed

Medicare patients

716

Average age 72

Services billed

1,954

417 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 44%
Diabetes 32%
Depression 22%
Chronic kidney disease 21%
Ischemic heart disease 20%
Osteoporosis 19%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $241
$241 — —
RINVOQ
  • AbbVie, Inc. $226
$226 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $153
$153 — —
Sucraid
  • QOL Medical, LLC $69
$69 — —
CREON
  • AbbVie, Inc. $65
$65 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record